Highlights

Market Capitalization
1.3M
Book Value
$0.06
Earnings Per Share (EPS)
-2.43
Wall Street Target Price
22.0
Profit Margin
0.0%
Operating Margin TTM
-501.34%
Return On Assets TTM
-41.14%
Return On Equity TTM
-203.37%
Revenue TTM
12.1M
Revenue Per Share TTM
0.41
Quarterly Revenue Growth YOY
-94.5%
Gross Profit TTM
0.0
EBITDA
-59.1M
Diluted Eps TTM
-2.43
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-6.59
EPS Estimate Next Quarter
-8.71

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Moderna, Inc.
Moderna, Inc.
-11.5%
19.92%
-1.43%
-63.9%
737.94%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.78%
11.32%
45.17%
82.69%
236.57%
Novo Nordisk A/s
Novo Nordisk A/s
-6.33%
26.68%
64.47%
198.6%
438.18%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.24%
14.68%
37.33%
146.48%
182.87%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.55
31.55
1.46
44.35
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.95
45.95
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.16
32.16
0.53
17.04
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Moderna, Inc.
Moderna, Inc.
Buy
$46.9B
737.94%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.9B
236.57%
31.55
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.6B
438.18%
45.95
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.0B
182.87%
32.16
39.46%

Insights on SQZB

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 12.01M → 178.0K (in $), with an average decrease of 98.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -16.77M → -23.63M (in $), with an average decrease of 41.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 64.5% return, outperforming this stock by 130.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.7% return, outperforming this stock by 293.4%

FAQs